This approach has been evaluated in mouse tumor models with promising results, showing that CD137 agonist antibodies have unique potential to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine (56). Here, TNFRSF9 is linked to neoplasm.